FDA says tirzepatide supply stabilized, clears path for compounding changes
Monday, June 8th, 2026 - The U.S. Food and Drug Administration has officially determined the nationwide shortage of tirzepatide injection, a dual GIP/GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, has been resolved, according to an agency update. The drug had been in shortage since 2022.
Regulation leads the story
The FDA's Center for Drug Evaluation and Research announced the end of the tirzepatide shortage, a status that had permitted pharmacies to prepare compounded versions of the injectable drug under federal policy. The agency said it continues to monitor the supply of GLP-1 and GIP/GLP-1 drugs.
Compounding pharmacies face a narrower path
With the shortage resolved, pharmacies operating under Section 503A and outsourcing facilities under Section 503B now face stricter conditions for compounding tirzepatide. The FDA's update on compounding inspections and actions notes that regulators are conducting oversight of these facilities. Industry groups like the Alliance for Pharmacy Compounding and the Outsourcing Facilities Association are tracking these developments.
Pipeline records keep retatrutide in focus
Clinical trials for newer peptide-based drugs continue. Trial records for investigational agents like retatrutide, a triple-agonist peptide, show ongoing studies in phases 2 and 3 for conditions including obesity and metabolic dysfunction-associated steatohepatitis (MASH). Data from these trials are being reviewed in peer-reviewed medical literature.
Sports rules remain separate
For athletes, the World Anti-Doping Agency's prohibited list includes peptide hormones, growth factors, and related substances. The WADA status page advises athletes to verify current rules, as the list is updated annually. GLP-1 receptor agonists are not explicitly listed in the digest's summary of prohibited categories.
Related reading
- For ongoing regulatory actions, see Medriva’s FDA warning letters tracker.
- Background on compounding categories is available in 503A vs. 503B compounding explained.
- Clinical analysis of the dual-agonist class is in semaglutide vs. tirzepatide.
- Pipeline updates for triple-agonists are tracked on the retatrutide page.
